San Francisco – March 23, 2017 – Cooley advised the underwriter on Prothena’s $155.3 million shelf-takedown offering of 2,700,000 ordinary shares. The underwriter has a 30-day option to purchase 405,000 additional ordinary shares.
Cantor Fitzgerald & Co. was the sole underwriter for the offering.
Prothena, which trades on The NASDAQ Global Select Market as “PRTA,” is a global, late-stage clinical biotechnology company with a clinical pipeline of novel therapeutic antibodies. Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.